Furosemide (oral): Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
m (Protected "Furosemide (oral)": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
||
| (44 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{Seealso|Furosemide (Injection)}} | |||
{{DrugProjectFormSinglePage01 | {{DrugProjectFormSinglePage01 | ||
|genericName=Furosemide | |genericName=Furosemide | ||
| Line 6: | Line 7: | ||
|indication=[[edema]] and [[hypertension]] | |indication=[[edema]] and [[hypertension]] | ||
|adverseReactions=[[hyperuricemia]], [[hypomagnesemia]], [[loss of appetite]], and [[spasm]] of [[bladder]] | |adverseReactions=[[hyperuricemia]], [[hypomagnesemia]], [[loss of appetite]], and [[spasm]] of [[bladder]] | ||
|fdaLIADAdult= | |fdaLIADAdult=====Indications==== | ||
====Indications==== | |||
=====Edema===== | =====Edema===== | ||
Furosemide is indicated in adults patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. | Furosemide is indicated in adults patients for the treatment of [[edema]] associated with [[congestive heart failure]], [[cirrhosis]] of the liver, and renal disease, including the [[nephrotic syndrome]]. furosemide is particularly useful when an agent with greater [[diuretic]] potential is desired. | ||
=====Hypertension===== | =====Hypertension===== | ||
Oral | Oral furosemide may be used in adults for the treatment of [[hypertension]] alone or in combination with other [[antihypertensive]] agents. Hypertensive patients who cannot be adequately controlled with [[thiazides]] will probably also not be adequately controlled with furosemide alone. | ||
====Dosage==== | ====Dosage==== | ||
| Line 20: | Line 19: | ||
======Adults====== | ======Adults====== | ||
The usual initial dose of furosemide is 20 to 80 mg given as a single dose. Ordinarily a prompt [[diuresis]] ensues. If needed, the same dose can be administered 6 to 8 hours later or the dose may be increased. The dose may be raised by 20 or 40 mg and given not sooner than 6 to 8 hours after the previous dose until the desired [[diuretic]] effect has been obtained. The individually determined single dose should then be given once or twice daily (eg, at 8 am and 2 pm). The dose of furosemide may be carefully titrated up to 600 mg/day in patients with clinically severe [[edematous]] states. | |||
[[Edema]] may be most efficiently and safely mobilized by giving furosemide on 2 to 4 consecutive days each week. | |||
When doses exceeding 80 mg/day are given for prolonged periods, careful clinical observation and laboratory monitoring are particularly advisable. | |||
When doses exceeding 80 mg/day are given for prolonged periods, careful clinical observation and laboratory monitoring are particularly advisable. | |||
======Geriatric patients====== | ======Geriatric patients====== | ||
In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range | In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range. | ||
=====Hypertension===== | =====Hypertension===== | ||
| Line 34: | Line 32: | ||
======Adults====== | ======Adults====== | ||
The usual initial dose of | The usual initial dose of furosemide for [[hypertension]] is 80 mg, usually divided into 40 mg twice a day. Dosage should then be adjusted according to response. If response is not satisfactory, add other [[antihypertensive]] agents. | ||
Changes in blood pressure must be carefully monitored when | Changes in [[blood pressure]] must be carefully monitored when furosemide is used with other [[antihypertensive]] drugs, especially during initial therapy. To prevent excessive drop in [[blood pressure]] the dosage of other agents should be reduced by at least 50 percent when furosemide is added to the regimen. As the [[blood pressure]] falls under the potentiating effect of furosemide, a further reduction in dosage or even discontinuation of other [[antihypertensive]] drugs may be necessary. | ||
======Geriatric patients====== | ======Geriatric patients====== | ||
In general, dose selection and dose adjustment for the elderly patient should be cautious, usually starting at the low end of the dosing range | In general, dose selection and dose adjustment for the elderly patient should be cautious, usually starting at the low end of the dosing range. | ||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of | |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of furosemide (Oral) in adult patients. | ||
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of | |offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of furosemide (Oral) in adult patients. | ||
|fdaLIADPed= | |fdaLIADPed= | ||
====Indications==== | ====Indications==== | ||
=====Edema===== | =====Edema===== | ||
Furosemide is indicated in pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. | Furosemide is indicated in pediatric patients for the treatment of [[edema]] associated with [[congestive heart failure]], [[cirrhosis]] of the liver, and renal disease, including the [[nephrotic syndrome]]. furosemide is particularly useful when an agent with greater [[diuretic]] potential is desired. | ||
====Dosage==== | ====Dosage==== | ||
=====Edema===== | =====Edema===== | ||
The usual initial dose of oral | The usual initial dose of oral furosemide in pediatric patients is 2 mg/kg body weight, given as a single dose. If the [[diuretic]] response is not satisfactory after the initial dose, dosage may be increased by 1 or 2 mg/kg no sooner than 6 to 8 hours after the previous dose. Doses greater than 6 mg/kg body weight are not recommended. For maintenance therapy in pediatric patients, the dose should be adjusted to the minimum effective level. | ||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of | |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of furosemide (Oral) in pediatric patients. | ||
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of | |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of furosemide (Oral) in pediatric patients. | ||
|contraindications=Furosemide is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide. | |contraindications=Furosemide is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide. | ||
|warnings=In patients with hepatic cirrhosis and ascites, | |warnings=In patients with [[hepatic cirrhosis]] and [[ascites]], furosemide therapy is best initiated in the hospital. In [[hepatic coma]] and in states of [[electrolyte]] depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate [[hepatic coma]]; therefore, strict observation is necessary during the period of diuresis. Supplemental [[potassium chloride]] and, if required, an [[aldosterone antagonist]] are helpful in preventing [[hypokalemia]] and [[metabolic alkalosis]]. | ||
If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, | If increasing [[azotemia]] and [[oliguria]] occur during treatment of severe progressive renal disease, furosemide should be discontinued. | ||
Cases of tinnitus and reversible or irreversible hearing impairment have been reported. Usually, reports indicate that | Cases of tinnitus and reversible or irreversible [[hearing impairment]] have been reported. Usually, reports indicate that furosemide [[ototoxicity]] is associated with rapid injection, severe renal impairment, doses exceeding several times the usual recommended dose, or concomitant therapy with [[aminoglycoside]] antibiotics, [[ethacrynic acid]], or other [[ototoxic]] drugs. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used). | ||
==Precautions== | ==Precautions== | ||
===General=== | ===General=== | ||
Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. As with any effective diuretic, electrolyte depletion may occur during | Excessive [[diuresis]] may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular [[thrombosis]] and [[embolism]], particularly in elderly patients. As with any effective [[diuretic]], electrolyte depletion may occur during furosemide therapy, especially in patients receiving higher doses and a restricted salt intake. Hypokalemia may develop with furosemide, especially with brisk [[diuresis]], inadequate oral electrolyte intake, when [[cirrhosis]] is present, or during concomitant use of [[corticosteroids]] or [[ACTH]]. [[Digitalis]] therapy may exaggerate metabolic effects of [[hypokalemia]], especially myocardial effects. | ||
All patients receiving | All patients receiving furosemide therapy should be observed for these signs or symptoms of fluid or electrolyte imbalance ([[hyponatremia]], [[hypochloremic alkalosis]], [[hypokalemia]], [[hypomagnesemia]] or [[hypocalcemia]]): [[dryness of mouth]], [[thirst]], [[weakness]], [[lethargy]], [[drowsiness]], [[restlessness]], [[muscle pain]]s or [[cramp]]s, muscular [[fatigue]], [[hypotension]], [[oliguria]], [[tachycardia]], [[arrhythmia]], or [[gastrointestinal disturbances]] such as [[nausea]] and [[vomiting]]. Increases in blood [[glucose]] and alterations in [[glucose tolerance test]]s (with abnormalities of the fasting and 2-hour postprandial sugar) have been observed, and rarely, precipitation of [[diabetes mellitus]] has been reported. | ||
Asymptomatic hyperuricemia can occur and gout may rarely be precipitated. | Asymptomatic [[hyperuricemia]] can occur and [[gout]] may rarely be precipitated. | ||
Patients allergic to sulfonamides may also be allergic to | Patients allergic to [[sulfonamides]] may also be allergic to furosemide. The possibility exists of exacerbation or activation of [[systemic lupus erythematosus]]. | ||
As with many other drugs, patients should be observed regularly for the possible occurrence of blood | As with many other drugs, patients should be observed regularly for the possible occurrence of [[blood dyscrasia]]s, liver or kidney damage, or other [[idiosyncratic reaction]]s. | ||
===Laboratory Tests=== | ===Laboratory Tests=== | ||
Serum electrolytes (particularly potassium), CO2, creatinine and BUN should be determined frequently during the first few months of | Serum [[electrolytes]] (particularly [[potassium]]), [[CO2]], [[creatinine]] and [[BUN]] should be determined frequently during the first few months of furosemide therapy and periodically thereafter. Serum and urine electrolyte determinations are particularly important when the patient is [[vomiting]] profusely or receiving parenteral fluids. Abnormalities should be corrected or the drug temporarily withdrawn. Other medications may also influence serum [[electrolytes]]. | ||
Reversible elevations of BUN may occur and are associated with dehydration, which should be avoided, particularly in patients with renal insufficiency. | Reversible elevations of [[BUN]] may occur and are associated with dehydration, which should be avoided, particularly in patients with [[renal insufficiency]]. | ||
Urine and blood glucose should be checked periodically in diabetics receiving | Urine and blood [[glucose]] should be checked periodically in [[diabetics]] receiving furosemide, even in those suspected of latent [[diabetes]]. | ||
Furosemide may lower serum levels of calcium (rarely cases of tetany have been reported) and magnesium. Accordingly, serum levels of these electrolytes should be determined periodically. | Furosemide may lower serum levels of [[calcium]] (rarely cases of [[tetany]] have been reported) and [[magnesium]]. Accordingly, serum levels of these electrolytes should be determined periodically. | ||
===Carcinogenesis, Mutagenesis, Impairment of Fertility=== | ===Carcinogenesis, Mutagenesis, Impairment of Fertility=== | ||
Furosemide was tested for carcinogenicity by oral administration in one strain of mice and one strain of rats. A small but significantly increased incidence of mammary gland carcinomas occurred in female mice at a dose 17.5 times the maximum human dose of 600 mg. There were marginal increases in uncommon tumors in male rats at a dose of 15 mg/kg (slightly greater than the maximum human dose) but not at 30 mg/kg. | Furosemide was tested for carcinogenicity by oral administration in one strain of mice and one strain of rats. A small but significantly increased incidence of [[mammary gland]] [[carcinomas]] occurred in female mice at a dose 17.5 times the maximum human dose of 600 mg. There were marginal increases in uncommon [[tumors]] in male rats at a dose of 15 mg/kg (slightly greater than the maximum human dose) but not at 30 mg/kg. | ||
Furosemide was devoid of mutagenic activity in various strains of Salmonella typhimurium when tested in the presence or absence of an in vitro metabolic activation system, and questionably positive for gene mutation in mouse lymphoma cells in the presence of rat liver S9 at the highest dose tested. | Furosemide was devoid of mutagenic activity in various strains of [[Salmonella typhimurium]] when tested in the presence or absence of an in vitro metabolic activation system, and questionably positive for gene mutation in mouse [[lymphoma]] cells in the presence of rat liver S9 at the highest dose tested. furosemide did not induce sister chromatid exchange in human cells in vitro, but other studies on chromosomal aberrations in human cells in vitro gave conflicting results. In Chinese hamster cells it induced [[chromosomal]] damage but was questionably positive for [[sister chromatid]] exchange. Studies on the induction by furosemide of [[chromosomal aberration]]s in mice were inconclusive. The urine of rats treated with this drug did not induce gene conversion in [[Saccharomyces cerevisiae]]. | ||
Furosemide produced no impairment of fertility in male or female rats, at 100 mg/kg/day (the maximum effective diuretic dose in the rat and 8 times the maximal human dose of 600 mg/day). | Furosemide produced no impairment of [[fertility]] in male or female rats, at 100 mg/kg/day (the maximum effective [[diuretic]] dose in the rat and 8 times the maximal human dose of 600 mg/day). | ||
|clinicalTrials=There is limited information regarding <i>Clinical Trials Experience</i> of | |clinicalTrials=There is limited information regarding <i>Clinical Trials Experience</i> of furosemide (Oral) in the drug label. | ||
|postmarketing=Adverse reactions are categorized below by organ system and listed by decreasing severity. | |postmarketing=Adverse reactions are categorized below by organ system and listed by decreasing severity. | ||
===Gastrointestinal System Reactions=== | ===Gastrointestinal System Reactions=== | ||
* [[Pancreatitis]] | |||
* [[Jaundice]] ([[intrahepatic cholestatic jaundice]]) | |||
* [[Anorexia]] | |||
* [[Oral]] and [[gastric irritation]] | |||
* [[Cramping]] | |||
* [[Diarrhea]] | |||
* [[Constipation]] | |||
* [[Nausea]] | |||
* [[Vomiting]] | |||
Systemic Hypersensitivity Reactions | ===Systemic Hypersensitivity Reactions=== | ||
* Systemic [[vasculitis]] | |||
* [[Interstitial nephritis]] | |||
* [[Necrotizing angiitis]] | |||
Central Nervous System Reactions | ===Central Nervous System Reactions=== | ||
* [[Tinnitus]] and [[hearing loss]] | |||
* [[Paresthesias]] | |||
* [[Vertigo]] | |||
* [[Dizziness]] | |||
* [[Headache]] | |||
* [[Blurred vision]] | |||
* [[Xanthopsia]] | |||
Hematologic Reactions | ===Hematologic Reactions=== | ||
* [[Aplastic anemia]] (rare) | |||
* [[Thrombocytopenia]] | |||
* [[Agranulocytosis]] (rare) | |||
* [[Hemolytic anemia]] | |||
* [[Leukopenia]] | |||
* [[Anemia]] | |||
Dermatologic-Hypersensitivity Reactions | ===Dermatologic-Hypersensitivity Reactions=== | ||
* [[Exfoliative dermatitis]] | |||
* [[Erythema multiforme]] | |||
* [[Purpura]] | |||
* [[Photosensitivity]] | |||
* [[Urticaria]] | |||
* [[Rash]] | |||
* [[Pruritus]] | |||
Cardiovascular Reaction | ===Cardiovascular Reaction=== | ||
Orthostatic hypotension may occur and be aggravated by alcohol, barbiturates or narcotics. | * [[Orthostatic hypotension]] may occur and be aggravated by [[alcohol]], [[barbiturates]], or [[narcotics]]. | ||
===Other Reactions=== | |||
* [[Hyperglycemia]] | |||
* [[Glycosuria]] | |||
* [[Hyperuricemia]] | |||
* [[Muscle spasm]] | |||
* [[Weakness]] | |||
* [[Restlessness]] | |||
* [[Urinary bladder]] [[spasm]] | |||
* [[Thrombophlebitis]] | |||
* [[Fever]] | |||
Whenever adverse reactions are moderate or severe, furosemide dosage should be reduced or therapy withdrawn. | |||
|drugInteractions=Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function. Except in life-threatening situations, avoid this combination. | |||
Furosemide should not be used concomitantly with [[ethacrynic acid]] because of the possibility of [[ototoxicity]]. Patients receiving high doses of [[salicylates]] concomitantly with furosemide, as in rheumatic disease, may experience [[salicylate]] toxicity at lower doses because of competitive renal excretory sites. | |||
Furosemide | Furosemide has a tendency to antagonize the [[skeletal muscle]] relaxing effect of [[tubocurarine]] and may potentiate the action of [[succinylcholine]]. | ||
[[Lithium]] generally should not be given with diuretics because they reduce [[lithium]]'s renal clearance and add a high risk of [[lithium]] toxicity. | |||
Furosemide may add to or potentiate the therapeutic effect of other [[antihypertensive]] drugs. Potentiation occurs with ganglionic or peripheral [[adrenergic]] blocking drugs. | |||
Furosemide may | Furosemide may decrease arterial responsiveness to [[norepinephrine]]. However, [[norepinephrine]] may still be used effectively. | ||
Simultaneous administration of [[sucralfate]] and furosemide may reduce the [[natriuretic]] and [[antihypertensive]] effects of furosemide. Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved. The intake of furosemide and sucralfate should be separated by at least two hours. | |||
One study in six subjects demonstrated that the combination of furosemide and [[acetylsalicylic acid]] temporarily reduced [[creatinine clearance]] in patients with [[chronic renal insufficiency]] There are case reports of patients who developed increased BUN, serum [[creatinine]] and serum [[potassium]] levels, and weight gain when furosemide was used in conjunction with [[NSAID]]s. | |||
Literature reports indicate that coadministration of [[indomethacin]] may reduce the [[natriuretic]] and [[antihypertensive]] effects of furosemide (furosemide) in some patients by inhibiting [[prostaglandin]] synthesis. [[Indomethacin]] may also affect plasma [[renin]] levels, [[aldosterone]] excretion, and [[renin]] profile evaluation. Patients receiving both [[indomethacin]] and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved. | |||
|useInPregnancyFDA= | |||
'''Pregnancy Category: C''' | |||
Furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits at 2, 4 and 8 times the maximal recommended human dose. There are no adequate and well-controlled studies in pregnant women. furosemide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. | |||
The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats and rabbits. | The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats and rabbits. | ||
Furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (2 times the maximal recommended human dose of 600 mg/day). In another study, a dose of 50 mg/kg (4 times the maximal recommended human dose of 600 mg/day) also caused maternal deaths and abortions when administered to rabbits between Days 12 and 17 of gestation. In a third study, none of the pregnant rabbits survived a dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede maternal deaths. | Furosemide caused unexplained maternal deaths and [[abortions]] in the rabbit at the lowest dose of 25 mg/kg (2 times the maximal recommended human dose of 600 mg/day). In another study, a dose of 50 mg/kg (4 times the maximal recommended human dose of 600 mg/day) also caused maternal deaths and abortions when administered to rabbits between Days 12 and 17 of gestation. In a third study, none of the pregnant rabbits survived a dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede maternal deaths. | ||
The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses derived from the treated dams as compared with the incidence in fetuses from the control group. | The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses derived from the treated dams as compared with the incidence in fetuses from the control group. | ||
|useInLaborDelivery=There is no FDA guidance on the use of | |useInLaborDelivery=There is no FDA guidance on the use of furosemide (Oral) during labor and delivery. | ||
|useInNursing=Because it appears in breast milk, caution should be exercised when | |useInNursing=Because it appears in breast milk, caution should be exercised when furosemide is administered to a nursing mother. | ||
|useInPed=There is no FDA guidance on the use of | |useInPed=There is no FDA guidance on the use of furosemide (Oral) with respect to pediatric patients. | ||
|useInGeri=Controlled clinical studies of furosemide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. | |useInGeri=Controlled clinical studies of furosemide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. | ||
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. | This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. | ||
|useInGender=There is no FDA guidance on the use of | |useInGender=There is no FDA guidance on the use of furosemide (Oral) with respect to specific gender populations. | ||
|useInRace=There is no FDA guidance on the use of | |useInRace=There is no FDA guidance on the use of furosemide (Oral) with respect to specific racial populations. | ||
|useInRenalImpair=There is no FDA guidance on the use of | |useInRenalImpair=There is no FDA guidance on the use of furosemide (Oral) in patients with renal impairment. | ||
|useInHepaticImpair=There is no FDA guidance on the use of | |useInHepaticImpair=There is no FDA guidance on the use of furosemide (Oral) in patients with hepatic impairment. | ||
|useInReproPotential=There is no FDA guidance on the use of | |useInReproPotential=There is no FDA guidance on the use of furosemide (Oral) in women of reproductive potentials and males. | ||
|useInImmunocomp=There is no FDA guidance on the use of | |useInImmunocomp=There is no FDA guidance on the use of furosemide (Oral) in patients who are immunocompromised. | ||
|administration= | |administration=Oral | ||
|monitoring=There is limited information regarding <i>Monitoring</i> of | |monitoring=There is limited information regarding <i>Monitoring</i> of furosemide (Oral) in the drug label. | ||
|overdose=The principal signs and symptoms of overdose with | |overdose=The principal signs and symptoms of overdose with furosemide are dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and are extensions of its diuretic action. | ||
The acute toxicity of | The acute toxicity of furosemide has been determined in mice, rats and dogs. In all three, the oral LD50 exceeded 1000 mg/kg body weight, while the intravenous LD50 ranged from 300 to 680 mg/kg. The acute intragastric toxicity in neonatal rats is 7 to 10 times that of adult rats. | ||
The concentration of | The concentration of furosemide in biological fluids associated with toxicity or death is not known. | ||
Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy). | Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as [[prostatic hypertrophy]]). | ||
Hemodialysis does not accelerate furosemide elimination. | Hemodialysis does not accelerate furosemide elimination. | ||
| Line 196: | Line 195: | ||
| verifiedrevid = 461114978 | | verifiedrevid = 461114978 | ||
| IUPAC_name = 4-chloro-2-(furan-2-ylmethylamino)- 5-sulfamoylbenzoic acid | | IUPAC_name = 4-chloro-2-(furan-2-ylmethylamino)- 5-sulfamoylbenzoic acid | ||
| image = | | image = furosemide.png | ||
| image2 = Furosemide-1Z9Y-3D-balls.png | | image2 = Furosemide-1Z9Y-3D-balls.png | ||
| CASNo_Ref = {{cascite|correct|CAS}} | | CASNo_Ref = {{cascite|correct|CAS}} | ||
| Line 237: | Line 236: | ||
| routes_of_administration = Oral, [[Intravenous therapy|IV]], [[Intramuscular injection|IM]] | | routes_of_administration = Oral, [[Intravenous therapy|IV]], [[Intramuscular injection|IM]] | ||
}} | }} | ||
|mechAction= | |mechAction=Investigations into the mode of action of furosemide have utilized micropuncture studies is rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the reabsorption of [[sodium]] and [[chloride]] not only in the proximal and distal tubules but also in the [[loop of Henle]]. The high degree of efficacy is largely due to this unique site of action. The action on the distal tubule is independent of any inhibitory effect on [[carbonic anhydrase]] and [[aldosterone]]. | ||
|structure=Furosemide is a diuretic which is an anthranilic acid derivative. | |structure=Furosemide is a [[diuretic]] which is an anthranilic acid derivative. furosemide for oral administration contain furosemide as the active ingredient and the following inactive ingredients: lactose anhydrous NF, magnesium stearate NF, starch NF, microcrystalline cellulose NF, sodium starch Glycolate NF, and colloidal silicon dioxide NF. Chemically, it is 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid. furosemide is available as white tablets for oral administration in dosage strengths of 20, 40 and 80 mg. furosemide is a white to off-white odorless crystalline powder. It is practically insoluble in water, sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids. | ||
The CAS Registry Number is 54-31-9. | The CAS Registry Number is 54-31-9. | ||
| Line 246: | Line 245: | ||
The molecular structure is as follows: | The molecular structure is as follows: | ||
[[File: | [[File:furosemideoral1.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | ||
|PD= | |PD= | ||
Recent evidence suggests that furosemide glucuronide is the only or at least the major [[biotransformation]] product of furosemide in man. furosemide is extensively bound to plasma proteins, mainly to [[albumin]]. Plasma concentrations ranging from 1 to 400 μg/mL are 91 to 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations. | |||
|PK= | The onset of [[diuresis]] following [[intravenous]] administration is within 5 minutes and somewhat later after [[intramuscular]] administration. The peak effect occurs within the first half hour. The duration of [[diuretic]] effect is approximately 2 hours. | ||
|PK= | |||
|nonClinToxic= | In fasted normal men, the mean [[bioavailability]] of furosemide from furosemide and furosemide oral solution is 64 % and 60%, respectively, of that from an intravenous injection of the drug. Although furosemide is more rapidly absorbed from the oral solution (50 minutes) than from the tablet (87 minutes), peak plasma levels and area under the plasma concentration-time curves do not differ significantly. Peak plasma concentrations increase with increasing dose but times-to-peak do not differ among doses. The terminal half-life of furosemide is approximately 2 hours. | ||
Significantly more furosemide is excreted in urine following the intravenous injection than after the tablet or oral solution. There are no significant differences between the two oral formulations in the amount of unchanged drug excreted in urine. | |||
|nonClinToxic= | |||
====Carcinogenesis, Mutagenesis, Impairment of Fertility==== | |||
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of | Furosemide was tested for carcinogenicity by oral administration in one strain of mice and one strain of rats. A small but significantly increased incidence of mammary gland [[carcinoma]]s occurred in female mice at a dose 17.5 times the maximum human dose of 600 mg. There were marginal increases in uncommon tumors in male rats at a dose of 15 mg/kg (slightly greater than the maximum human dose) but not at 30 mg/kg. | ||
Furosemide was devoid of mutagenic activity in various strains of ''[[Salmonella typhimurium]]'' when tested in the presence or absence of an in vitro metabolic activation system, and questionably positive for gene mutation in mouse lymphoma cells in the presence of rat liver S9 at the highest dose tested. furosemide did not induce [[sister chromatid]] exchange in human cells in vitro, but other studies on chromosomal aberrations in human cells in vitro gave conflicting results. In Chinese hamster cells it induced chromosomal damage but was questionably positive for [[sister chromatid]] exchange. Studies on the induction by furosemide of chromosomal aberrations in mice were inconclusive. The urine of rats treated with this drug did not induce gene conversion in [[Saccharomyces cerevisiae]]. | |||
Furosemide produced no impairment of [[fertility]] in male or female rats, at 100 mg/kg/day (the maximum effective diuretic dose in the rat and 8 times the maximal human dose of 600 mg/day). | |||
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of furosemide (Oral) in the drug label. | |||
|howSupplied=Furosemide 20 mg are supplied as white, round tablets in Bottles of 100 (NDC 64125-116-01), and 1000 (NDC 64125-116-10). The 20 mg tablets are imprinted with "EP 116" on one side and plain on the other. | |howSupplied=Furosemide 20 mg are supplied as white, round tablets in Bottles of 100 (NDC 64125-116-01), and 1000 (NDC 64125-116-10). The 20 mg tablets are imprinted with "EP 116" on one side and plain on the other. | ||
Furosemide 40 mg are supplied as white, round, scored tablets in Bottles of 100 (NDC 64125-117-01) and 1000 (NDC 64125-117-10). The 40 mg tablets are imprinted with "EP 117" on one side and "40" on the other. | |||
Furosemide 80 mg are supplied as white, round, scored tablets in Bottles of 100 (NDC 64125-118-01) and 500 (NDC 64125-118-05). The 80 mg tablets are imprinted with "EP 118" on one side and "80" on the other. | |||
Note: Dispense in well-closed, light-resistant containers. Exposure to light might cause a slight discoloration. Discolored tablets should not be dispensed. | Note: Dispense in well-closed, light-resistant containers. Exposure to light might cause a slight discoloration. Discolored tablets should not be dispensed. | ||
| Line 266: | Line 270: | ||
Tested by USP Dissolution Test 2 | Tested by USP Dissolution Test 2 | ||
Store at 25° C (77° F); excursions permitted to 15 to 30° C (59 to 86° F). | Store at 25° C (77° F); excursions permitted to 15 to 30° C (59 to 86° F). | ||
|fdaPatientInfo= | |fdaPatientInfo=Patients receiving furosemide should be advised that they may experience symptoms from excessive fluid and/or [[electrolyte]] losses. | ||
The [[postural hypotension]] that sometimes occurs can usually be managed by getting up slowly. Potassium supplements and/or dietary measures may be needed to control or avoid [[hypokalemia]]. | |||
Patients with [[diabetes mellitus]] should be told that furosemide may increase blood [[glucose]] levels and thereby affect urine glucose tests. The skin of some patients may be more sensitive to the effects of sunlight while taking furosemide. | |||
[[Hypertensive]] patients should avoid medications that may increase [[blood pressure]], including over-the-counter products for appetite suppression and cold symptoms. | |||
|alcohol=Orthostatic hypotension may occur and be aggravated by alcohol, barbiturates or narcotics. | |alcohol=[[Orthostatic hypotension]] may occur and be aggravated by alcohol, barbiturates or narcotics.<ref>{{Cite web| title = DailyMed - furosemide - furosemide tablet| url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=79d9aef8-cfb9-4f6e-ac15-f830d7ea2324}}</ref> | ||
|brandNames= | |brandNames=Furosemide | ||
|lookAlike=N/A | |lookAlike=N/A | ||
|packLabel=[[File: | |packLabel= | ||
[[File:furosemideoral2.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:furosemideoral3.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:furosemideoral4.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:furosemideoral5.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:furosemideoral6.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:furosemideoral7.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
[[File:furosemideoral8.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | |||
}} | |||
[[Category:Diuretics]] | |||
[[Category:Loop diuretics]] | |||
[[Category:Sulfonamides]] | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] | |||
Latest revision as of 16:23, 20 August 2015
For patient information regarding Furosemide, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Furosemide (oral) is a diuretic that is FDA approved for the treatment of edema and hypertension. Common adverse reactions include hyperuricemia, hypomagnesemia, loss of appetite, and spasm of bladder.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications
Edema
Furosemide is indicated in adults patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. furosemide is particularly useful when an agent with greater diuretic potential is desired.
Hypertension
Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.
Dosage
Edema
Therapy should be individualized according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response.
Adults
The usual initial dose of furosemide is 20 to 80 mg given as a single dose. Ordinarily a prompt diuresis ensues. If needed, the same dose can be administered 6 to 8 hours later or the dose may be increased. The dose may be raised by 20 or 40 mg and given not sooner than 6 to 8 hours after the previous dose until the desired diuretic effect has been obtained. The individually determined single dose should then be given once or twice daily (eg, at 8 am and 2 pm). The dose of furosemide may be carefully titrated up to 600 mg/day in patients with clinically severe edematous states.
Edema may be most efficiently and safely mobilized by giving furosemide on 2 to 4 consecutive days each week.
When doses exceeding 80 mg/day are given for prolonged periods, careful clinical observation and laboratory monitoring are particularly advisable.
Geriatric patients
In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range.
Hypertension
Therapy should be individualized according to the patient's response to gain maximal therapeutic response and to determine the minimal dose needed to maintain the therapeutic response.
Adults
The usual initial dose of furosemide for hypertension is 80 mg, usually divided into 40 mg twice a day. Dosage should then be adjusted according to response. If response is not satisfactory, add other antihypertensive agents.
Changes in blood pressure must be carefully monitored when furosemide is used with other antihypertensive drugs, especially during initial therapy. To prevent excessive drop in blood pressure the dosage of other agents should be reduced by at least 50 percent when furosemide is added to the regimen. As the blood pressure falls under the potentiating effect of furosemide, a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary.
Geriatric patients
In general, dose selection and dose adjustment for the elderly patient should be cautious, usually starting at the low end of the dosing range.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of furosemide (Oral) in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of furosemide (Oral) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Indications
Edema
Furosemide is indicated in pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. furosemide is particularly useful when an agent with greater diuretic potential is desired.
Dosage
Edema
The usual initial dose of oral furosemide in pediatric patients is 2 mg/kg body weight, given as a single dose. If the diuretic response is not satisfactory after the initial dose, dosage may be increased by 1 or 2 mg/kg no sooner than 6 to 8 hours after the previous dose. Doses greater than 6 mg/kg body weight are not recommended. For maintenance therapy in pediatric patients, the dose should be adjusted to the minimum effective level.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of furosemide (Oral) in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of furosemide (Oral) in pediatric patients.
Contraindications
Furosemide is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.
Warnings
In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis.
If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued.
Cases of tinnitus and reversible or irreversible hearing impairment have been reported. Usually, reports indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, doses exceeding several times the usual recommended dose, or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used).
Precautions
General
Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. As with any effective diuretic, electrolyte depletion may occur during furosemide therapy, especially in patients receiving higher doses and a restricted salt intake. Hypokalemia may develop with furosemide, especially with brisk diuresis, inadequate oral electrolyte intake, when cirrhosis is present, or during concomitant use of corticosteroids or ACTH. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially myocardial effects.
All patients receiving furosemide therapy should be observed for these signs or symptoms of fluid or electrolyte imbalance (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia or hypocalcemia): dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting. Increases in blood glucose and alterations in glucose tolerance tests (with abnormalities of the fasting and 2-hour postprandial sugar) have been observed, and rarely, precipitation of diabetes mellitus has been reported.
Asymptomatic hyperuricemia can occur and gout may rarely be precipitated.
Patients allergic to sulfonamides may also be allergic to furosemide. The possibility exists of exacerbation or activation of systemic lupus erythematosus.
As with many other drugs, patients should be observed regularly for the possible occurrence of blood dyscrasias, liver or kidney damage, or other idiosyncratic reactions.
Laboratory Tests
Serum electrolytes (particularly potassium), CO2, creatinine and BUN should be determined frequently during the first few months of furosemide therapy and periodically thereafter. Serum and urine electrolyte determinations are particularly important when the patient is vomiting profusely or receiving parenteral fluids. Abnormalities should be corrected or the drug temporarily withdrawn. Other medications may also influence serum electrolytes.
Reversible elevations of BUN may occur and are associated with dehydration, which should be avoided, particularly in patients with renal insufficiency.
Urine and blood glucose should be checked periodically in diabetics receiving furosemide, even in those suspected of latent diabetes.
Furosemide may lower serum levels of calcium (rarely cases of tetany have been reported) and magnesium. Accordingly, serum levels of these electrolytes should be determined periodically.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Furosemide was tested for carcinogenicity by oral administration in one strain of mice and one strain of rats. A small but significantly increased incidence of mammary gland carcinomas occurred in female mice at a dose 17.5 times the maximum human dose of 600 mg. There were marginal increases in uncommon tumors in male rats at a dose of 15 mg/kg (slightly greater than the maximum human dose) but not at 30 mg/kg.
Furosemide was devoid of mutagenic activity in various strains of Salmonella typhimurium when tested in the presence or absence of an in vitro metabolic activation system, and questionably positive for gene mutation in mouse lymphoma cells in the presence of rat liver S9 at the highest dose tested. furosemide did not induce sister chromatid exchange in human cells in vitro, but other studies on chromosomal aberrations in human cells in vitro gave conflicting results. In Chinese hamster cells it induced chromosomal damage but was questionably positive for sister chromatid exchange. Studies on the induction by furosemide of chromosomal aberrations in mice were inconclusive. The urine of rats treated with this drug did not induce gene conversion in Saccharomyces cerevisiae.
Furosemide produced no impairment of fertility in male or female rats, at 100 mg/kg/day (the maximum effective diuretic dose in the rat and 8 times the maximal human dose of 600 mg/day).
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trials Experience of furosemide (Oral) in the drug label.
Postmarketing Experience
Adverse reactions are categorized below by organ system and listed by decreasing severity.
Gastrointestinal System Reactions
- Pancreatitis
- Jaundice (intrahepatic cholestatic jaundice)
- Anorexia
- Oral and gastric irritation
- Cramping
- Diarrhea
- Constipation
- Nausea
- Vomiting
Systemic Hypersensitivity Reactions
Central Nervous System Reactions
Hematologic Reactions
Dermatologic-Hypersensitivity Reactions
Cardiovascular Reaction
- Orthostatic hypotension may occur and be aggravated by alcohol, barbiturates, or narcotics.
Other Reactions
- Hyperglycemia
- Glycosuria
- Hyperuricemia
- Muscle spasm
- Weakness
- Restlessness
- Urinary bladder spasm
- Thrombophlebitis
- Fever
Whenever adverse reactions are moderate or severe, furosemide dosage should be reduced or therapy withdrawn.
Drug Interactions
Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function. Except in life-threatening situations, avoid this combination.
Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity. Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity.
Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
Furosemide may decrease arterial responsiveness to norepinephrine. However, norepinephrine may still be used effectively.
Simultaneous administration of sucralfate and furosemide may reduce the natriuretic and antihypertensive effects of furosemide. Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved. The intake of furosemide and sucralfate should be separated by at least two hours.
One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide (furosemide) in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
Use in Specific Populations
Pregnancy
Pregnancy Category: C
Furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits at 2, 4 and 8 times the maximal recommended human dose. There are no adequate and well-controlled studies in pregnant women. furosemide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats and rabbits.
Furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (2 times the maximal recommended human dose of 600 mg/day). In another study, a dose of 50 mg/kg (4 times the maximal recommended human dose of 600 mg/day) also caused maternal deaths and abortions when administered to rabbits between Days 12 and 17 of gestation. In a third study, none of the pregnant rabbits survived a dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede maternal deaths.
The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses derived from the treated dams as compared with the incidence in fetuses from the control group.
Labor and Delivery
There is no FDA guidance on the use of furosemide (Oral) during labor and delivery.
Nursing Mothers
Because it appears in breast milk, caution should be exercised when furosemide is administered to a nursing mother.
Pediatric Use
There is no FDA guidance on the use of furosemide (Oral) with respect to pediatric patients.
Geriatic Use
Controlled clinical studies of furosemide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.
Gender
There is no FDA guidance on the use of furosemide (Oral) with respect to specific gender populations.
Race
There is no FDA guidance on the use of furosemide (Oral) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of furosemide (Oral) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of furosemide (Oral) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of furosemide (Oral) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance on the use of furosemide (Oral) in patients who are immunocompromised.
Administration and Monitoring
Administration
Oral
Monitoring
There is limited information regarding Monitoring of furosemide (Oral) in the drug label.
Overdosage
The principal signs and symptoms of overdose with furosemide are dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and are extensions of its diuretic action.
The acute toxicity of furosemide has been determined in mice, rats and dogs. In all three, the oral LD50 exceeded 1000 mg/kg body weight, while the intravenous LD50 ranged from 300 to 680 mg/kg. The acute intragastric toxicity in neonatal rats is 7 to 10 times that of adult rats.
The concentration of furosemide in biological fluids associated with toxicity or death is not known.
Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy).
Hemodialysis does not accelerate furosemide elimination.
Pharmacology
| |
| |
Furosemide (oral)
| |
| Systematic (IUPAC) name | |
| 4-chloro-2-(furan-2-ylmethylamino)- 5-sulfamoylbenzoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | C03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox |
| Mol. mass | 330.745 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | 43-69% |
| Metabolism | hepatic and renal glucuronidation |
| Half life | up to 100 minutes |
| Excretion | renal 66%, biliary 33% |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status |
Template:Unicode Prescription only |
| Routes | Oral, IV, IM |
Mechanism of Action
Investigations into the mode of action of furosemide have utilized micropuncture studies is rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the reabsorption of sodium and chloride not only in the proximal and distal tubules but also in the loop of Henle. The high degree of efficacy is largely due to this unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.
Structure
Furosemide is a diuretic which is an anthranilic acid derivative. furosemide for oral administration contain furosemide as the active ingredient and the following inactive ingredients: lactose anhydrous NF, magnesium stearate NF, starch NF, microcrystalline cellulose NF, sodium starch Glycolate NF, and colloidal silicon dioxide NF. Chemically, it is 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid. furosemide is available as white tablets for oral administration in dosage strengths of 20, 40 and 80 mg. furosemide is a white to off-white odorless crystalline powder. It is practically insoluble in water, sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids.
The CAS Registry Number is 54-31-9.
It has a molecular formula of C12H11ClN2O5S and a molecular weight of 330.75.
The molecular structure is as follows:
Pharmacodynamics
Recent evidence suggests that furosemide glucuronide is the only or at least the major biotransformation product of furosemide in man. furosemide is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 to 400 μg/mL are 91 to 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations. The onset of diuresis following intravenous administration is within 5 minutes and somewhat later after intramuscular administration. The peak effect occurs within the first half hour. The duration of diuretic effect is approximately 2 hours.
Pharmacokinetics
In fasted normal men, the mean bioavailability of furosemide from furosemide and furosemide oral solution is 64 % and 60%, respectively, of that from an intravenous injection of the drug. Although furosemide is more rapidly absorbed from the oral solution (50 minutes) than from the tablet (87 minutes), peak plasma levels and area under the plasma concentration-time curves do not differ significantly. Peak plasma concentrations increase with increasing dose but times-to-peak do not differ among doses. The terminal half-life of furosemide is approximately 2 hours. Significantly more furosemide is excreted in urine following the intravenous injection than after the tablet or oral solution. There are no significant differences between the two oral formulations in the amount of unchanged drug excreted in urine.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
Furosemide was tested for carcinogenicity by oral administration in one strain of mice and one strain of rats. A small but significantly increased incidence of mammary gland carcinomas occurred in female mice at a dose 17.5 times the maximum human dose of 600 mg. There were marginal increases in uncommon tumors in male rats at a dose of 15 mg/kg (slightly greater than the maximum human dose) but not at 30 mg/kg.
Furosemide was devoid of mutagenic activity in various strains of Salmonella typhimurium when tested in the presence or absence of an in vitro metabolic activation system, and questionably positive for gene mutation in mouse lymphoma cells in the presence of rat liver S9 at the highest dose tested. furosemide did not induce sister chromatid exchange in human cells in vitro, but other studies on chromosomal aberrations in human cells in vitro gave conflicting results. In Chinese hamster cells it induced chromosomal damage but was questionably positive for sister chromatid exchange. Studies on the induction by furosemide of chromosomal aberrations in mice were inconclusive. The urine of rats treated with this drug did not induce gene conversion in Saccharomyces cerevisiae.
Furosemide produced no impairment of fertility in male or female rats, at 100 mg/kg/day (the maximum effective diuretic dose in the rat and 8 times the maximal human dose of 600 mg/day).
Clinical Studies
There is limited information regarding Clinical Studies of furosemide (Oral) in the drug label.
How Supplied
Furosemide 20 mg are supplied as white, round tablets in Bottles of 100 (NDC 64125-116-01), and 1000 (NDC 64125-116-10). The 20 mg tablets are imprinted with "EP 116" on one side and plain on the other.
Furosemide 40 mg are supplied as white, round, scored tablets in Bottles of 100 (NDC 64125-117-01) and 1000 (NDC 64125-117-10). The 40 mg tablets are imprinted with "EP 117" on one side and "40" on the other.
Furosemide 80 mg are supplied as white, round, scored tablets in Bottles of 100 (NDC 64125-118-01) and 500 (NDC 64125-118-05). The 80 mg tablets are imprinted with "EP 118" on one side and "80" on the other.
Note: Dispense in well-closed, light-resistant containers. Exposure to light might cause a slight discoloration. Discolored tablets should not be dispensed.
Tested by USP Dissolution Test 2
Store at 25° C (77° F); excursions permitted to 15 to 30° C (59 to 86° F).
Images
Package and Label Display Panel
Patient Counseling Information
Patients receiving furosemide should be advised that they may experience symptoms from excessive fluid and/or electrolyte losses. The postural hypotension that sometimes occurs can usually be managed by getting up slowly. Potassium supplements and/or dietary measures may be needed to control or avoid hypokalemia. Patients with diabetes mellitus should be told that furosemide may increase blood glucose levels and thereby affect urine glucose tests. The skin of some patients may be more sensitive to the effects of sunlight while taking furosemide. Hypertensive patients should avoid medications that may increase blood pressure, including over-the-counter products for appetite suppression and cold symptoms.
Precautions with Alcohol
Orthostatic hypotension may occur and be aggravated by alcohol, barbiturates or narcotics.[1]
Brand Names
Furosemide
Look-Alike Drug Names
N/A
Drug Shortage Status
References
The contents of this FDA label are provided by the National Library of Medicine.